St. Joseph's/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA 31405.
St. Joseph's/Candler Health System, Inc., 5353 Reynolds Street, Savannah, GA 31405.
Int J Antimicrob Agents. 2018 Mar;51(3):508-510. doi: 10.1016/j.ijantimicag.2017.12.031. Epub 2018 Jan 9.
Advancements in rapid diagnostics have helped to identify nutritionally variant streptococci (NVS) as an increasing cause of infective endocarditis (IE). This case report highlights the challenges in susceptibility testing and the importance of appropriate empiric treatment for Granulicatella adiacens, and provides considerations for future practice guideline recommendations. Guidelines for treatment of IE caused by NVS are currently limited to patients with native valve disease. We present a patient with presumed prosthetic valve endocarditis caused by G. adiacens, with clinically relevant resistance to recommended first-line agents (penicillin and ceftriaxone), who was successfully treated with 8 weeks of intravenous (IV) vancomycin. Vancomycin is currently recommended as an alternate therapy for patients intolerant of penicillins, but we believe vancomycin should be considered a first-line empiric treatment option for IE when the identified organism is G. adiacens and susceptibility testing is not readily available.
快速诊断技术的进步有助于将营养变异链球菌(NVS)确定为感染性心内膜炎(IE)的一个日益增加的病因。本病例报告强调了药敏试验的挑战和适当经验性治疗对颗粒奈瑟菌的重要性,并为未来实践指南建议提供了考虑因素。目前,治疗由 NVS 引起的 IE 的指南仅限于患有原生瓣膜疾病的患者。我们介绍了一名患有疑似人工瓣膜心内膜炎的患者,该患者由颗粒奈瑟菌引起,对推荐的一线药物(青霉素和头孢曲松)具有临床相关的耐药性,经 8 周静脉(IV)万古霉素治疗后成功治愈。万古霉素目前被推荐作为不耐受青霉素的患者的替代治疗方法,但我们认为,当鉴定出的病原体是颗粒奈瑟菌且药敏试验不易获得时,万古霉素应被视为 IE 的一线经验性治疗选择。